Targeting <i>SLC7A11</i> /xCT improves radiofrequency ablation efficacy of HCC by dendritic cells mediated anti‐tumor immune response

Abstract

After RFA treatment in patients with liver cancer, the expression of <i>SLC7A11</i>/xCT and the proportion of DCs in the TME were significantly increased. <i>SLC7A11</i>/xCT is a poor prognostic marker for liver cancer and is mainly expressed in DCs in the TME. Targeting xCT in DCs combined with RFA significantly enhances anti-tumor immunity, suppressing tumor growth and offering a promising strategy for improved therapeutic outcomes in liver cancer.